in vitro News and Research

RSS

U.S. patent for Celsis IVT's LiverPool products

Celsis International is pleased to announce that the United States Patent and Trademark Office today issued U.S. Patent No. 7,604,929 to Celsis In Vitro Technologies (Celsis IVT). This patent generally covers processes by which the company creates its unique LiverPool(TM) products for drug discovery research.

20 Oct 2009

IntegraMed America expands its Attain IVF treatment financing offerings

IntegraMed America, Inc., the nation’s leading manager of specialty outpatient healthcare facilities in the emerging, technology-focused medical niches of fertility and vein care, today announced that it has expanded its Attain™ IVF (In Vitro Fertilization) family of treatment financing offerings to include the Attain IVF Multi-Cycle Program.

20 Oct 2009

Substantial price reduction for 24 Chromosome Aneuploidy Screening

Gene Security Network, Inc. (GSN) today announced a substantial price reduction for its 24 Chromosome Aneuploidy Screening with Parental SupportTM. Effective immediately, pricing has been restructured to a single flat fee for testing of up to 24 embryos in an in vitro fertilization (IVF) cycle.

20 Oct 2009

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Mother Nature has provided the lizard with a unique ability to regrow body tissue that is damaged or torn ― if its tail is pulled off, it grows right back. She has not been quite so generous with human beings. But we might be able to come close, thanks to new research from Tel Aviv University.

20 Oct 2009

Scientists find cause for lupuslike disease in mice

Macrophages, the scavenger cells of the body's immune system, are responsible for disposing of dying cells. Stanford University School of Medicine researchers have identified one pathway in this important process in mice that, if disrupted, causes a lupuslike autoimmune disease.

19 Oct 2009

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

ChemDiv, Inc. of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.

19 Oct 2009

Chinese SFDA approves China Medical Technologies' SPR System

China Medical Technologies, Inc., a leading China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic products, today announced that the Company has received approval for its SPR- based analysis system (the "SPR System") from the State Food and Drug Administration of China (the "SFDA").

19 Oct 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Fate Therapeutics announces human iPSC generation using a combination of small molecules

Fate Therapeutics, Inc. announced today the generation of human induced-pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming.

19 Oct 2009

ADI and CeTeCancer collaborate for research project

Radient Pharmaceuticals Corporation, a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer -- a Chilean-based research laboratory -- to validate the effectiveness of Radient Pharmaceuticals' Onko-Sure™ in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Nucleix, Ltd., an emerging life science company specializing in forensic DNA analysis, announced that company researchers today presented its DNA authentication technology, a novel assay to distinguish between in-vivo (real) and in-vitro (fake) DNA, at the 20th International Symposium on Human Identification in Las Vegas, Nevada.

15 Oct 2009

Harvard researchers unite in fight against antibiotic resistance

The National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH) have awarded $5 million to an interdisciplinary group of Harvard researchers to launch the "Harvard-wide Program on Antibiotic Resistance."

14 Oct 2009

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Researchers at Texas State University-San Marcos have completed initial testing of a cancer chemotherapeutic and anti-retroviral compound with promising results.

14 Oct 2009

Sequella receives Phase 1 SBIR grant for developing SQ641

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.

13 Oct 2009

Diagnostics industry in Asia Pacific poised to present more growth opportunities

The global diagnostics industry has witnessed strong growth over the past few years. According to Frost & Sullivan, the diagnostics and monitoring sectors are poised to present more growth opportunities. According to Nitin Naik, Vice President of Frost & Sullivan's Asia Pacific Medical Technologies Division, the diagnostics and monitoring sectors in Asia Pacific are projected to provide more growth opportunities on the basis of the technology spending being channelled in these areas (80 percent).

13 Oct 2009

Melanocyte-like cells in heart and pulmonary veins contribute to atrial fibrillation

The source and mechanisms underlying the abnormal heart beats that initiate atrial fibrillation (Afib), the most common type of abnormal heart beat, have not been well determined. However, a group of researchers at the University of Pennsylvania, Philadelphia, has now identified a population of cells that are like pigment producing cells in the skin (melanocytes) in the atria of the heart and pulmonary veins of mice and humans and uncovered evidence in mice that these cells contribute to Afib.

13 Oct 2009

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

According to new research from the Monell Center and the Mount Sinai School of Medicine, certain common herbicides and lipid-lowering fibrate drugs act in humans to block T1R3, a nutrient-sensing taste receptor also present in intestine and pancreas.

12 Oct 2009

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Crescendo Biologics today announces it has raised GBP4.5 million in a seed-funding round to advance the development of its fragment antibody technology platforms. The funding round was led by Sofinnova Partners, a Paris-based venture capital firm, with Aitua, Avlar BioVentures and the Rainbow Seed Fund also participating.

12 Oct 2009

in vitro News and Research

U.S. patent for Celsis IVT's LiverPool products

IntegraMed America expands its Attain IVF treatment financing offerings

Substantial price reduction for 24 Chromosome Aneuploidy Screening

Tel Aviv University develops scaffold to regenerate damaged bones and tissues

Scientists find cause for lupuslike disease in mice

Viriom picks ChemDiv's Russian subsidiary for development of innovative HIV compounds

Chinese SFDA approves China Medical Technologies' SPR System

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Fate Therapeutics announces human iPSC generation using a combination of small molecules

ADI and CeTeCancer collaborate for research project

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

DNA authentication technology to distinguish between in-vivo and in-vitro DNA

Harvard researchers unite in fight against antibiotic resistance

Researchers test Orizon Research's ALKA-V6 silicon-based compound

Sequella receives Phase 1 SBIR grant for developing SQ641

Diagnostics industry in Asia Pacific poised to present more growth opportunities

Melanocyte-like cells in heart and pulmonary veins contribute to atrial fibrillation

Compounds that bock nutrient-sensing receptor may impact obesity and diabetic conditions

Crescendo Biologics raises funds to advance the development of its fragment antibody technology platforms

Driving innovation in drug discovery with in vitro biology solutions eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News